Novavax Inc. NVAX, -2.07% released more extensive data on its Phase 1 trial of a vaccine for COVID-19 Wednesday, and shares rose about 4% in after-hours trading. Novavax previously released findings from the study that said the vaccine candidate induced immune responses and was well-tolerated, but more more data from the study was published Wednesday in The New England Journal of Medicine. "The rapid publication of Phase 1 results from our trial in a prestigious peer-reviewed journal reflects both the importance of the data and the urgent need for an effective vaccine to slow the COVID-19 pandemic," Novavax's president of research and development, Gregory Glenn, said in a news release. After closing with a 2.1% decline at $102.90 in Wednesday's regular session, shares topped $107 in after-hours trading following release of the information. Novavax is one of at least 23 companies working on solutions to COVID-19 amid a global pandemic. Novavax shares have gained nearly 2,500% so far this year.
Reprinted from yahoofinance, the copyrights all reserved by the original author.
Peringatan: Pendapat yang disampaikan sepenuhnya merupakan milik penulis dan tidak mencerminkan posisi resmi Followme. Followme tidak bertanggung jawab atas keakuratan, kelengkapan, atau keandalan informasi yang disediakan, serta tidak bertanggung jawab atas tindakan apa pun yang diambil berdasarkan konten ini, kecuali dinyatakan secara tertulis.
Tinggalkan pesan Anda sekarang